Literature DB >> 28777203

A Review of Alprazolam Use, Misuse, and Withdrawal.

Nassima Ait-Daoud1, Allan Scott Hamby, Sana Sharma, Derek Blevins.   

Abstract

: Alprazolam is one of the most widely prescribed benzodiazepines for the treatment of generalized anxiety disorder and panic disorder. Its clinical use has been a point of contention as most addiction specialists consider it to be highly addictive, given its unique psychodynamic properties which limit its clinical usefulness, whereas many primary care physicians continue to prescribe it for longer periods than recommended. Clinical research data has not fully shed light on its "abuse liability," yet it is one of the most frequently prescribed benzodiazepines. "Abuse liability" is the degree to which a psychoactive drug has properties that facilitate people misusing it, or becoming addicted to it, and is commonly used in the literature. We have replaced it in our manuscript with "misuse liability" as it reflects a more updated terminology consistent with the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). In this paper, we have reviewed alprazolam's indications for use, its effect on pregnant women, misuse liability, withdrawal syndrome, pharmacodynamic properties, and suggest better clinical prescription practice of alprazolam by presenting an indepth theory of its clinical effects with use and withdrawal.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28777203      PMCID: PMC5846112          DOI: 10.1097/ADM.0000000000000350

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  63 in total

1.  The seeking and liking potentials of alprazolam.

Authors:  C Schmauss; S Apelt; H M Emrich
Journal:  Am J Psychiatry       Date:  1988-01       Impact factor: 18.112

2.  A difficult alprazolam withdrawal.

Authors:  S J Kantor
Journal:  J Clin Psychopharmacol       Date:  1986-04       Impact factor: 3.153

3.  The behavioral effects of benzodiazepines following long-term use.

Authors:  I Lucki; K Rickels
Journal:  Psychopharmacol Bull       Date:  1986

4.  The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.

Authors:  Steven Moylan; John Staples; Stephanie Alison Ward; Jan Rogerson; Dan J Stein; Michael Berk
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

5.  Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam.

Authors:  D Bentué-Ferrer; J M Reymann; O Tribut; H Allain; E Vasar; M Bourin
Journal:  Eur Neuropsychopharmacol       Date:  2001-02       Impact factor: 4.600

6.  Benzodiazepines are Prescribed More Frequently to Patients Already at Risk for Benzodiazepine-Related Adverse Events in Primary Care.

Authors:  David S Kroll; Harry Reyes Nieva; Arthur J Barsky; Jeffrey A Linder
Journal:  J Gen Intern Med       Date:  2016-05-13       Impact factor: 5.128

7.  Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.

Authors:  L R Dolovich; A Addis; J M Vaillancourt; J D Power; G Koren; T R Einarson
Journal:  BMJ       Date:  1998-09-26

8.  Exacerbation of psychosis after discontinuation of carbamazepine treatment.

Authors:  C W Heh; J Sramek; J Herrera; J Costa
Journal:  Am J Psychiatry       Date:  1988-07       Impact factor: 18.112

9.  Failure of lorazepam to treat alprazolam withdrawal in a critically ill patient.

Authors:  Gaurav Sachdev; Gail Gesin; A Britton Christmas; Ronald F Sing
Journal:  World J Crit Care Med       Date:  2014-02-04

Review 10.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

View more
  17 in total

1.  Nonmedical use of alprazolam in the UK: Results from a nationally representative survey.

Authors:  Joanna Hockenhull; Elise Amioka; Joshua C Black; Colleen M Haynes; Paul I Dargan; Richard C Dart; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2019-06-05       Impact factor: 4.335

2.  Voltage-clamp evidence of GABAA receptor subunit-specific effects: pharmacodynamic fingerprint of chlornordiazepam, the major active metabolite of mexazolam, as compared to alprazolam, bromazepam, and zolpidem.

Authors:  Hélder Fernandes; Vânia Batalha; Ellen Braksator; Simon Hebeisen; Maria João Bonifácio; Maria Augusta Vieira-Coelho; Patrício Soares-da-Silva
Journal:  Pharmacol Rep       Date:  2022-09-12       Impact factor: 3.919

3.  Anxiety and Stress-Related Disorders.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-06-17

4.  Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.

Authors:  Andrew J Melaragno
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-06-17

5.  Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis.

Authors:  Kevin Y Xu; Jacob T Borodovsky; Ned Presnall; Carrie M Mintz; Sarah M Hartz; Laura J Bierut; Richard A Grucza
Journal:  Am J Psychiatry       Date:  2021-03-03       Impact factor: 19.242

6.  Comparison of Dental Benzodiazepine Prescriptions From the U.S., England, and Australia From 2013 to 2018.

Authors:  Leanne Teoh; Wendy Thompson; Colin C Hubbard; Walid Gellad; Kathryn Finn; Katie J Suda
Journal:  Am J Prev Med       Date:  2021-03-26       Impact factor: 6.604

7.  Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models.

Authors:  Dan Liu; Linzhong Li; Amin Rostami-Hodjegan; Frederic Y Bois; Masoud Jamei
Journal:  AAPS J       Date:  2020-07-17       Impact factor: 4.009

8.  A survey of prescribing practices by general dentists in Australia.

Authors:  L Teoh; R J Marino; K Stewart; M J McCullough
Journal:  BMC Oral Health       Date:  2019-08-22       Impact factor: 2.757

9.  Efficacy and Safety of Jiawei Suanzaoren Decoction Combined with Lorazepam for Chronic Insomnia: A Parallel-Group Randomized Controlled Trial.

Authors:  Ming-Fen Song; Li-Qiong Chen; Qiong-Yan Shao; Lin-Lin Hu; Wen-Juan Liu; Yong-Hua Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-08       Impact factor: 2.629

10.  Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.

Authors:  David K Conn; David B Hogan; Lori Amdam; Keri-Leigh Cassidy; Peter Cordell; Christopher Frank; David Gardner; Morris Goldhar; Joanne M-W Ho; Christopher Kitamura; Nancy Vasil
Journal:  Can Geriatr J       Date:  2020-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.